PNRAX
Price
$52.73
Change
-$1.57 (-2.89%)
Updated
Dec 18 closing price
VFIAX
Price
$543.40
Change
-$16.50 (-2.95%)
Updated
Dec 18 closing price
Ad is loading...

PNRAX vs VFIAX

Header iconPNRAX vs VFIAX Comparison
Open Charts PNRAX vs VFIAXBanner chart's image
Putnam Research A
Price$52.73
Change-$1.57 (-2.89%)
VolumeN/A
CapitalizationN/A
Vanguard 500 Index Admiral
Price$543.40
Change-$16.50 (-2.95%)
VolumeN/A
CapitalizationN/A
PNRAX vs VFIAX Comparison Chart
Loading...
View a ticker or compare two or three
VS
PNRAX vs. VFIAX commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PNRAX is a Hold and VFIAX is a StrongBuy.

FUNDAMENTALS
Fundamentals
VFIAX has more cash in the bank: 1.37T vs. PNRAX (606M). VFIAX pays higher dividends than PNRAX: VFIAX (1.32) vs PNRAX (0.25). PNRAX was incepted earlier than VFIAX: PNRAX (29 years) vs VFIAX (24 years). PNRAX is a more actively managed with annual turnover of: 35.00 vs. VFIAX (2.00). PNRAX has a lower initial minimum investment than VFIAX: PNRAX (0) vs VFIAX (3000). VFIAX annual gain was more profitable for investors over the last year : 23.64 vs. PNRAX (18.23). VFIAX return over 5 years is better than : 83.03 vs. PNRAX (58.50).
PNRAXVFIAXPNRAX / VFIAX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence29 years24 years-
Gain YTD18.02323.55277%
Front LoadN/AN/A-
Min. Initial Investment03000-
Min. Initial Investment IRAN/AN/A-
Net Assets606M1.37T0%
Annual Yield % from dividends0.251.3219%
Returns for 1 year18.2323.6477%
Returns for 3 years19.7827.1373%
Returns for 5 years58.5083.0370%
Returns for 10 years115.58185.0162%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NVEE19.32-0.18
-0.92%
NV5 Global Inc
MG8.92-0.16
-1.76%
Mistras Group
GATX155.21-5.90
-3.66%
GATX Corp
DDOG150.20-6.71
-4.28%
Datadog
SABS3.34-0.69
-17.12%
SAB Biotherapeutics